Illumina (NASDAQ:ILMN) Insider Scott Davies Sells 615 Shares

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the transaction, the insider directly owned 21,568 shares in the company, valued at approximately $3,450,880. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 0.9%

Shares of Illumina stock traded up $1.44 during midday trading on Monday, reaching $164.40. The company had a trading volume of 2,190,386 shares, compared to its average volume of 1,870,274. The stock has a fifty day moving average price of $133.73 and a 200 day moving average price of $132.09. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $24.87 billion, a PE ratio of 29.89, a P/E/G ratio of 2.70 and a beta of 1.50. Illumina, Inc. has a fifty-two week low of $78.79 and a fifty-two week high of $165.97.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Canaccord Genuity Group dropped their price target on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Finally, Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $138.38.

Institutional Investors Weigh In On Illumina

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Illumina by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after buying an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co purchased a new stake in Illumina in the third quarter worth approximately $2,319,000. Caprock Group LLC purchased a new stake in Illumina in the third quarter worth approximately $1,479,000. Capital World Investors boosted its stake in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after buying an additional 911,843 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.